Mercy BioAnalytics, Inc. is a leader in the development of extracellular vesicle-based liquid biopsies aimed at the early detection of cancer. The company’s patented Mercy Halo™ platform leverages biomarker co-localization to analyze blood-based extracellular vesicles, which carry unique cancer signatures, to identify early-stage cancers when they are most treatable. Initially focusing on ovarian and lung cancers, Mercy BioAnalytics is committed to enhancing early cancer detection to improve patient outcomes and quality of life.